AstraZeneca (AZN) Issues Encouraging Update on Durvalumab ATLANTIC Trial in NSCLC
- Wall Street falls with Amazon; S&P 500 posts sixth straight month of gains
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- 'I'm CEO.' New Book Outlines Merger Conversations Between Elon Musk and Tim Cook
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
AstraZeneca (NYSE: AZN) provided an update on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage therapy in patients with locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations. An initial analysis supports durvalumab’s clinical activity, with durable responses and an established safety profile in these difficult-to-treat patients.
ATLANTIC investigated the efficacy and tolerability of durvalumab in patients who received at least two prior systemic treatment regimens including platinum-based chemotherapy, and who have limited options for further therapy. A full evaluation of the data is ongoing and the results will be presented at a scientific congress in 2016.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “As we have seen in other studies, durvalumab has demonstrated expected clinical activity and durable response in these heavily pre-treated patients. As previously communicated, the treatment and regulatory landscape in lung cancer is evolving. We now believe it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast advancing development programme focused primarily on novel combinations.”
A comprehensive durvalumab registration programme is underway across multiple tumour types, stages of disease, and lines of therapy both as monotherapy and in combination. This forms part of AstraZeneca’s late-stage immuno-oncology programme and includes more than 9,000 patients in 16 clinical trials in lung, bladder, head & neck, and other cancers, summarised below.
DURVALUMAB DEVELOPMENT PROGRAMME
Status as of Year-To-Date and Q3 2015 Financial results on 5 November 2015
Next update with FY 2015 Results on 4 February 2016
Line of treatment
|ADJUVANT||III||N/A||Stage Ib-IIIa NSCLC||durvalumab vs placebo||Data expected 2020||Recruiting|
|PACIFIC||III||N/A||Stage III unresect-able NSCLC||durvalumab vs placebo||Data expected 2017||Recruiting|
|ATLANTIC||II||3rd line||PD-L1 pos. NSCLC||durvalumab (single arm)||Full data 2016||-|
|ARCTIC||III||3rd line||NSCLC||durvalumab vs SoC (PD-L1 pos.) or durvalumab vs tremelimumab vs durva + treme vs SoC (PD-L1 neg.)||Data expected 2017||Recruiting|
|MYSTIC||III||1st line||NSCLC (PFS endpoint)||durvalumab vs durva + treme vs SoC||Data expected 2017||First patient dosed|
|NEPTUNE||III||1st line||NSCLC (OS endpoint)||durva + treme vs SoC||Data expected 2018||Awaiting first patient dosed|
|-||III||1st line||NSCLC||durvalumab + chemotherapy +/- tremelimumab||In preparation|
|CAURAL||III||2nd line||T790M+ NSCLC||osimertinib vs osimertinib + durvalumab||Data expected 2018||Initiated enrolment; currently on partial clinical hold to characterise incidence of interstitial lung disease|
METASTATIC HEAD AND NECK CANCER
Line of treatment
|HAWK||II||2nd line||PD-L1 pos. SCCHN||durvalumab (single arm)||Data expected|
Indication granted FDA Fast Track designation
|CONDOR||II||2nd line||PD-L1 neg. SCCHN||durvalumab vs tremelimumab vs durva + treme||Data expected 2017||Recruiting|
|EAGLE||III||2nd line||SCCHN||durvalumab vs durva + treme vs SoC||Data expected 2018||In preparation|
|KESTREL||III||1st line||SCCHN||durvalumab vs durva + treme vs SoC||Data expected 2018||In preparation|
METASTATIC BLADDER CANCER
Line of treatment
|DANUBE||III||1st line||Cisplatin chemo-therapy-eligible/ineligible||durvalumab vs durva + treme vs SoC|
Data expected 2018
First patient dosed
OTHER TUMOUR TYPES
Line of treatment
|-||II||2nd/3rd line||Metastatic gastric cancer||durvalumab vs tremelimumab vs durva + treme|
|-||II||2nd line||Unresect-able liver cancer||durvalumab vs tremelimumab vs durva + treme||In preparation|
|ALPS||II||2nd line||Unresect-able liver cancer||durva + treme (single arm)||In preparation|
SoC = Standard of Care, PFS = Progression Free Survival, OS = Overall Survival
About durvalumab (MEDI4736)
Durvalumab is an investigational human monoclonal antibody directed against PD-L1. Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer. Durvalumab is being investigated in an extensive clinical trial programme, as monotherapy or in combination with tremelimumab, in NSCLC, head and neck, gastric, pancreatic, bladder and blood cancers.
About the ATLANTIC trial
ATLANTIC is a Phase II, non-comparative, open-label, multi-centre, international trial of durvalumab in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Towne Bank (TOWN) Names Brad E. Schwartz President and CEO
- Lexicon Pharma (LXRX) Announces Craig Granowitz, M.D., Ph.D. Joins as Senior Vice President and Chief Medical Officer
- I-Mab Biopharma (IMAB) Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!